r. Scott Raymond Ward, MS, B.Sc., serves as the Managing Director of Sightline Partners. He served as Venture Partner at Sightline Partners. Mr. Ward serves as the President and Founder of Raymond Holdings. He served as Senior Vice President of Medtronic Minimed, Inc. since May 2004 and served as President of Vascular since May 2004. He served as Senior Vice President and President of CardioVascular business at Medtronic, Inc. since May 2007 and was responsible for all worldwide operations of the CardioVascular Business including the Coronary, Peripheral, Endovascular, Structural Heart Disease (SHD) and Revascularization and Surgical Therapies (RST) Businesses. Mr. Ward served as Senior Vice President and President of Vascular Business at Medtronic, Inc. from May 3, 2004 to May 2007. He served as Senior Vice President and President of Neurological and Diabetes Business – operating segment of Medtronic, Inc. from February 2002 to May 2004, was responsible for the global Neurological, Neurologic Technologies, Diabetes, Gastroenterology and Urology businesses and served as the President of Neurological from January 2000 to January 2002. He served as Vice President and General Manager of Medtronic’s Drug Delivery Business from 1995 to 2000 and Director of Medtronic NeuroVentures. Before moving into general management, Mr. Ward was responsible for the Neurological Ventures Organization which successfully developed new therapies for the treatment of pain, spasticity and Parkinson’s disease. He also held various research, regulatory and business development positions since joining Medtronic in 1981 as a research technician. He has been the Chairman of Creganna-Tactx Medical Devices, Inc. since May 24, 2012 and Director since July 12, 2011. He serves as the Chairman of Gillette Children’s Specialty Healthcare and iScience Interventional. He serves as a Director of AUM Cardiovascular, Inc. He has been a Director of SurModics, Inc. since September 2010. He has been a Non-Executive Director of ImpediMed Limited since July 12, 2013. He has been a Director of Respicardia, Inc., since November 1, 2012. He also serves on the Board of Aleva Neurotherapeutics, SA, and Apica Cardiovascular, Ltd. He served as the Chairman of MAP Pharmaceuticals, Inc. from February 18, 2011 to March 1, 2013. He served as Director of MAP Pharmaceuticals Inc. from September 25, 2008 to March 1, 2013. He has over 30 years of experience in medical technology, including 15 years as an operating business leader. Mr. Ward received M.S. in Toxicology and Pharmacology in 1983, both from the University of Minnesota, a B.S. in Genetics and Cell Biology in 1981, from the University of Minnesota.